33 results on '"Kunz, Claudia"'
Search Results
2. Freeze-Drying From Organic Co-Solvent Systems, Part 2: Process Modifications to Reduce Residual Solvent Levels and Improve Product Quality Attributes
3. Merits and Limitations of Dynamic Vapor Sorption Studies on the Morphology and Physicochemical State of Freeze-Dried Products
4. Factors Influencing the Retention of Organic Solvents in Products Freeze-Dried From Co-Solvent Systems
5. Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS
6. Freeze-Drying From Organic Cosolvent Systems, Part 1: Thermal Analysis of Cosolvent-Based Placebo Formulations in the Frozen State
7. Data from Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma
8. Supplementary Materials and Methods, Figures S1 - S4 from Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma
9. Suppl Figures from A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma
10. CONSORT from A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma
11. Acknowledgement from A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma
12. Safety and Efficacy of Single HDIT101 Infusion Versus Episodic Valacyclovir Standard-of-Care in Patients with Chronic Recurrent Anogenital Herpes Simplex Virus 2 (HSV-2) Infection: A Multicentre, Parallel-Group Design, Randomised, Double-Blind, Double-Dummy Phase 2 Trial
13. Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients
14. Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile
15. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients
16. PREDICTING PSYCHOTHERAPY UTILIZATION FOR PATIENTS WITH BORDERLINE PERSONALITY DISORDER
17. Longitudinal analysis of quality of life following treatment with asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.
18. Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients
19. ATIM-13. ASUNERCEPT PLUS RADIOTHERAPY IN RELAPSED GLIOBLASTOMA. UPDATE ON FIVE YEARS OVERALL SURVIVAL OF STUDY NCT01071837 AND DEVELOPMENT OF A POPULATION-PK - TUMOR GROWTH INHIBITION - SURVIVAL MODEL
20. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma
21. APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis , on behalf of the Groupe Francophone des Myélodysplasies
22. Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study
23. Abstract 464: Methylation of a single CpG site in the CD95-ligand promoter is a biomarker predicting the response to therapy with APG101 in glioblastoma
24. Safety and efficacy of the CD95-ligand inhibitor APG101 in transfusion-dependent patients with low risk MDS: Interim results from a phase I study.
25. INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1) IN ASTHMA BRONCHIALE
26. A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma
27. The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study
28. Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma.
29. The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS)
30. Untersuchungen zur PDE-Ausstattung unterschiedlicher Zelllinien und Xenograft-Tumoren sowie zum Wirkmechanismus substituierter Pteridine
31. APG101_CD_002: A phase II, randomized, open-label, multicenter study of weekly APG101 plus reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma.
32. Influence of lithium cations on prolyl peptide bonds
33. Intracellular localization of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine in membrane structures impeding the inhibition of cytosolic cyclic AMP-specific phosphodiesterase
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.